By Michael Erman and Mrinalika Roy Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile obesity drug ...

Pfizer on Tuesday hailed a study of a weight-loss-drug candidate while forecasting a profit decline due to the impact of the Trump administration’s policies on pricing and tariffs.

Pfizer (PFE) stock falls as the company posts mid-stage trial data for obesity therapy PF’3944. Read more here.

Pfizer (NYSE:PFE) reported positive Phase 2b VESPER-3 data for its monthly injectable GLP-1 obesity therapy acquired from ...

The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...

A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.

Pfizer's latest trial data on a new obesity drug raises questions about its tolerability, leading to a slight drop in the ...

Pfizer reported weight-loss results for a monthly GLP-1 obesity injection that it acquired as part of the $10 billion Metsera ...

Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call ...

The drugmaker shared limited early results from a Metsera obesity treatment as investors weigh its $10 billion acquisition and declining Covid sales.

Pfizer released trial data on a new obesity drug, raising concerns about tolerability. Despite a stock drop, the company aims ...

Pfizer (PFE) stock drops as analysts weigh in on mid-stage trial data for the company's obesity drug and its Q4 2025 earnings. Read more here.